HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection

NCT02660905 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Human Immunodeficiency Virus
Hepatitis C, Chronic

Interventions

DRUG: E/C/F/TAF;
DRUG: Ledipasvir-Sofosbuvir

Sponsor

Ottawa Hospital Research Institute

Collaborators

[object Object]
[object Object]